ANTHEM

Anthem Biosciences Ltd.

NSE: ANTHEM

BSE: 544449

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Biotechnology

957.80+24.3 (+2.60%)

8 Sep, 3:30 PM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

99.7 / 100

Value Score

11.3 / 100

Price Momentum Score

84.2 / 100

QVM Score

79.8 / 100

Key Metrics

Market Cap

52574.30

P/E (TTM)

91.28

P/B

17.28

P/S (TTM)

26.26

EV/EBITDA

65.19

CAPE (5Y)

119.42

ROE (TTM)

21.71

ROCE (TTM)

24.90

ROA (TTM)

18.98

Avg 3Y ROE

20.86

Earnings 3Y CAGR

15.00

Sales 3Y CAGR

26.20

Sales 5Y CAGR

14.00

Debt/Equity

0.02

Consensus TP

900.00

Strong Buy %

62.50

Promoter Holding

71.42

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Anthem Biosciences Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 84.2 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

84.2 / 100

High and stable ROE

The company reported strong ROE of 21.71% for 12-month ended 30 Jun 2026 and ROE improved marginally by 88 bps from 1 year ago

What is ROE (FY)?

High and stable operating margin

The company reported strong operating margin of 32.73% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 122 bps from 1 year ago

What is Operating profit margin?

Moderate EPS growth and above median growth of industry

The company delivered moderate EPS growth of 13.23% for 12-month ended 30 Jun 2026 and the growth was 52.8 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.02 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.03 in the last 1 year

What is Debt to Equity?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 91.28 indicates that the stock is expensive on a standalone basis and is at a 64.26% premium to industry median P/E

What is P/E Ratio?

Median: 55.57

Value 91.28

-53.69450.34

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -1.93% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Not enough data

Low revenue growth and in line with median growth of industry

The company delivered low revenue growth of -2.14% for 12-month ended 30 Jun 2026 and the growth was 0.0 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: -2.14

Value -2.14

-72.3212.34

Low dividend yield

The company has a low dividend yield of 0.21%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 69.2 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

69.2 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Anthem Biosciences Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Anthem Biosciences Ltd. Shareholding Pattern

Quarterly breakdown of Anthem Biosciences Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2013	Mar 2014	Mar 2015	Sep 2016	Sep 2017	Sep 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Jul 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	4.84	0.00	87.94	84.00	84.00	84.00	84.00	84.00	82.96	76.85	76.84	74.69	74.69	74.69	74.68	71.42
Indian Promoter	0.00	0.00	83.61	84.00	84.00	84.00	84.00	84.00	82.96	76.85	76.84	74.69	74.69	74.69	74.68	71.42
Foreign Promoter	4.84	0.00	4.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	5.10	8.89	8.96	12.83	16.06
Mutual Funds / UTI	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	2.21	6.68	6.89	10.12	11.15
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.17	0.42	0.44	0.93	1.59
Govt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.50	1.66	1.37	1.28	2.57
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.21	0.11	0.27	0.50	0.74
Non-Institution	95.16	100.00	12.06	16.00	16.00	16.00	16.00	16.00	17.04	23.15	23.16	20.22	16.42	16.35	12.49	12.53
Bodies Corporate	0.00	0.00	0.00	3.94	0.00	0.00	0.00	0.00	0.00	8.33	12.09	3.99	3.93	3.88	0.26	0.25
Others (incl. Retail) No. of shareholders	95.16 0	100.00 0	12.06 0	12.06 3	16.00 4	16.00 4	16.00 4	16.00 4	17.04 6	14.82 6	11.07 5	16.23 8,25,417	12.49 2,17,341	12.47 1,99,208	12.23 1,79,963	12.28 1,72,895

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Midcap 150	0.17%	146 / 149
2	NIFTY Large Midcap 250	0.09%	243 / 250
3	Nifty 500	0.04%	324 / 499
4	Nifty Total Market	0.03%	382 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Anthem Biosciences Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Viridity Tone LLP Designated Person	March-2026	Market Sale (Disposal) 12th Mar 2026	3.79 %	₹ 617.93	2.03 cr	₹ 1255.25 cr

Corporate Actions

History of Anthem Biosciences Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 2/share
Record date: 26th Jun 2026Ex-date: 25th Jun 2026
Announced on: 19th May 2026

Company Profile

Overview of Anthem Biosciences Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company’s segments include CRDMO and Speciality Ingredients. The Company helps new an...

Key personnel

Mr. Mohammed Gawir Gawir Baig

Chief Financial Officer

Ms. Divya Prasad

Compliance Officer, Company Secretary

Mr. Ajay BhardwajD

Chief Executive Officer, Managing Director (Promoter)

Mr. K Ravindra ChandrappaD

Whole Time Director, Chief Operating Officer

Mr. Ganesh SambasivamD

Director (Promoter)

Mr. Satish Chander SubbannaD

Nominee Director

Ms. Shubha KulkarniD

Independent Director

Mr. Subramanian MadhavanD

Independent Director

View all

Incorporated on

13 Jun 2006

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

2,282

IPO date

21 Jul 2025

Free Float

8,93,57,881

Website

https://www.anthembio.com/

Phone no.

+9108066724000

Address

No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area Phase 1, Bommasandra, BANGALORE, 560099, India

Frequently Asked Questions

What is the current share price of Anthem Biosciences Ltd.?

The current share price of Anthem Biosciences Ltd. is ₹ 957.80 as of 8 Sep 2026.

What is the market capitalisation of Anthem Biosciences Ltd.?

The market capitalisation of Anthem Biosciences Ltd. stands at ₹ 52,574.30 Cr.

What is the PE ratio of Anthem Biosciences Ltd.?

The Price-to-Earnings (PE) ratio of Anthem Biosciences Ltd. is 91.28 as of the latest trailing twelve months data.

What is the ROE and ROCE of Anthem Biosciences Ltd.?

Anthem Biosciences Ltd. has a Return on Equity (ROE) of 21.71% and a Return on Capital Employed (ROCE) of 24.90% as per the latest financial reports.

What is the 52-week high and low of Anthem Biosciences Ltd.?

The 52-week high of Anthem Biosciences Ltd. is - and the 52-week low is -.

What is the dividend yield of Anthem Biosciences Ltd.?

The dividend yield of Anthem Biosciences Ltd. is 0.21% based on the current market price.

What is the FII and DII holding in Anthem Biosciences Ltd.?

Foreign Institutional Investors (FII) hold 2.57%, Domestic Institutional Investors (DII) hold 12.74% and retail/public investors hold 12.28% of Anthem Biosciences Ltd. shares.

What sector does Anthem Biosciences Ltd. belong to?

Anthem Biosciences Ltd. operates in the Healthcare sector. 100% of analysts have a Buy or Strong Buy rating on Anthem Biosciences Ltd. with a consensus target price of ₹ 900.00, implying 3.59% downside from current levels.

What is the beta of Anthem Biosciences Ltd.?

The beta of Anthem Biosciences Ltd. is 0.61, indicating its price volatility relative to the broader market. Over the past 1 year, Anthem Biosciences Ltd. has delivered an absolute return of 14.60%.

What is the RSI of Anthem Biosciences Ltd.?

The 14-day Relative Strength Index (RSI) of Anthem Biosciences Ltd. is 64.58, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Anthem Biosciences Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Anthem Biosciences Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Company Profile

Corporate Actions